Език: EN EN
← Назад към резултатите
Набира участници NCT05106387

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

Заболявания: Chronic Kidney Disease (CKD)

Спонсор: Regeneron Pharmaceuticals

Налично на: БГ
Обобщение
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Кой може да участва
Inclusion Criteria: 1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\]. 2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide informed consent signed by study patient or legally acceptable representative Exclusion Criteria: 1.There are no exclusion criteria for this study. Note: Other protocol defined Inclusion/Exclusion criteria may apply
Интервенции
Noninterventional
DRUG
Места на провеждане 9
САЩ (9)
John Hopkins Hospital
Baltimore , Maryland
Comprehensive Transplant Center
Chicago , Illinois
Cedars-Sinai Medical Center
Los Angeles , California
University of Minnesota
Minneapolis , Minnesota
Yale University of Medicine
New Haven , Connecticut
New York University Langone Health
New York , New York
University of California Irvine
Orange , California
Penn Transplant Institute
Philadelphia , Pennsylvania
Connie Frank Transplant Center at UCSF
San Francisco , California
Технически детайли
Статус
Набира участници
Вид изследване
OBSERVATIONAL
Пол
Мъже и жени
Минимална възраст
18 Years
Максимална възраст
70 Years
Здрави доброволци
Не
Начална дата
19.10.2023
Крайна дата
23.02.2028
Регистрационен номер
NCT05106387
Източник
clinicaltrials.gov
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.